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A novel styryl diphenylamine derivative reverts the transformed phenotype
of human fibrosarcoma HT1080 ceils
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Department ofCancer Research, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co. Ltd, 135 Komakado I Chome,
Gotemba-shi, Shizuoka 412, Japan.
Smq Revertant cells, which can be isolated from transformed cells, are flat, non-transformed variants
that have contnbuted to the idaton of nisms involved in cell transformation. We have disovered
that a nove styryl diphenylamine derivative converts human fibrosarcoma HT1080 cells into revertant cels
This compound iuces flat cell morphology and causes a dcrease proliferative rate. The flat revertant ced
not only exhibt a reducton m saturation density at confluence, but also lose the ability to proliferate m soft
agar. Furthermore, their tumorigenicty is reduced when injected s.c. into athymic nude mice. The compound
alters morphology in three out of seven cancer cel ines and has a potent growth inhibitory effect in six of
these lines. In contrast, it has only low klev of cytotoxicty for three normal diploid cell lines. These findings
indicate that this styryl diphenylamine derivative has the potential to suppress the malignant phenotype of
cancer cedls without profound cytotoxity in non-transformed cells.
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Revertant cells are flat, non-transformed variants that can be
isolated from populations of tranformed cells through
artificial techniques (Wyke, 1971; Gazdar et al., 1974; Vogel
and Pollack, 1974; Varmus et al., 1981). Such isolated rever-
tant cells may be a useful tool for understanding isms
of tumorigenic transformation and it is apparent that studies
of revertant cells have contributed to the progress of
moleular oncology. To date, a variety of compounds which
revert the phenotype of oncogene-transfected cells have been
reported: azatyrosin (Krzyzosiak et al., 1992; Kyprianou et
al., 1992), okadaic acid (Sakai et al., 1989), herbimycin A
(Uehara et al., 1989), tyrosine kinase inhibitors (Umezawa et
al., 1991), trichostatin A (Sugita et al., 1992a) and depudecin
(Sugita et al., 1992b); most of these have been isolated from
micro-organism cultured media.
We have discovered a synthetic low molecular weight com-
pound, a styryl diphenylamin derivative, which induces flat
revertants in human fibrosarcoma HT1080 cells derived from
naturally occurring tumours. In the initial study we screened
derivatives of lobenzarit disodium, an agent used to treat
rheumatoid arthritis (Ohsugi et al., 1983), to study the
modulation of cytokine induction. We noticed that a few of
the derivatives could direty alter the morphology of certain
tumour cell lines which expresed a flat revertant-like
phenotype. Among these, HT1080 cells were found to be an
appropnate candidate in terms of exhibiting definite altera-
tions in cell morphology. Since we were interested in explor-
ing new compounds that have a stronger ability to alter the
morphology of HT1080 cells into the flat revertant, we
started to synthesise scores of such derivatives. Finally, we
found a novel and potent derivative, RX465, dissimilar to
conventional anti-cancer drugs in chemical strucre. We
predicted that the styryl diphenylamine derivative would be
able to reduce the malignant phenotype of tumour ells,
because the cell morphology induced by this compound is
closely related to that ofthe flat revertant, showing reduction
of mutant N-ras gene product p21 (p21IN), which par-
ticipates in the control of this transformed phenotype as
shown in HT1080 cells using a suicide technique (Paterson et
al., 1987).
In the present paper, we describe how revertant cells
induced with this novel styryl diphenylamine derivative are
transformed back from human malignant fibrosarcoma
HT1080 cells and lose their malignancy in terms of rapid
proliferation rate with cellular pilng, a high saturation den-
sity at confluence, anchorage-independent growth in soft agar
and tumorigenicity in nude mice. We also show the effects of
this compound on other cancer cell lines and some normal
diploid cel ines in terms of growth and morphology.
M sateria amd
Compound
A styryl diphenylamine derivative, RX-465 (Figure 1), was
syntheised in our laboratory. A 10 mM stock solution of the
compound was ed in dimethylsulphoxide (DMSO) and
diluted with medium before addition to cells. The final con-
centration of DMSO in the medium was 0.1%, and had no
effect on the morphology or growth of HT1080 cells as well
as other cell ines used in this paper.
Cell culture
HT1O8O human fibrosarcoma, K-BALB Kirste murine sar-
coma virus-transformed BALB/3T3, L-929 derived from
murine connective tissue, T24 human bladder carcinoma,
PA-I human ovarian teratocarcinoma, human diploid fibro-
blast MRC-5, WI-38 and IMR-90 were purchased from
ATCC (Rockville, MD, USA). P388 murine lukaemia and
B16 murine melanoma were obtaied from the Cancer
Chemotherapy Center, Japanese Foundation for Cancer
Research (Tokyo, Japan). All tumour cell ines were cultured
in Dulbecco's modified Eagle medim (DMEM; Gibco,
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Grand Island, NY, USA) containing 10% fetal bovine serum
(FBS) (Gibco) under 5% carbon dioxide in 100% humidified
air at 37C. Normal diploid cell lines were cultured in Eagle's
minimum essential medium (Gibco) containing 10% FBS.
The cell lines were tested for and found to be free of mycop-
lasma contamination with a mycoplasma T.C. rapid detec-
tion system (Gen-Probe, San Diego. CA. USA).
Cell growth assay
Cells were inoculated into a 24-well plate (Falcon, Lincoln
Park, NJ, USA) at 2.5 x I0 -I x I0- cells per well on day 0,
and the next day were treated with medium either containing
various concentrations of RX-465 or in the absence of RX-
465 as a control. The medium was changed on days 3 and 5.
At the appropriate time interval. the cells were harvested
with 0.05% trypsin-0.53 mM EDTA in Hanks' balanced salt
solution (HBSS) (Gibco) and the number of cells was
counted with a Coulter Counter ZB1 (Coulter Electronics,
Hialeah, FL, USA). IC50 value (concentration producing
50% cell growth inhibition) was calculated on the basis of
the number of cells treated with or without vanrous concen-
trations of RX-465 when control cells reached a saturation
density.
Anchorage-independent cell growth assay,
HT1080 cells were grown with or without 1 liM, 2iLM RX-
465 for 2 days. The cells were harvested with 0.05% tryp-
sin-0.1% EDTA in phosphate-buffered saline (PBS) and
washed with fresh medium several times to remove RX-465.
After confirming their ability to exclude trypan blue dye, they
were plated at 1 x I03 cells per well onto a 24-well tissue
culture plate in 0.3% agar with DMEM supplemented with
10% FBS. After 12 days the number of colonies per well was
counted.
Tumorigenicitv assay
HT1080 cells were grown with or without 2 m RX-465 for
48 h. and the cells were harvested with 0.05% trypsin-0.1I%
EDTA in PBS. These cells, freed from RX-465 by a washing
procedure, were checked for viability by trypan blue exclu-
sion. Approximately 1 x 106 viable cells were inoculated s.c.
into athymic (Nu Nu) male mice (CSK Research Park,
Tokyo, Japan) aged 6 weeks. Animals were fed ad libitwn an
autoclaved diet and tap water and maintained in stenlised
cages. After 17 days. the tumours were excised and weighed.
Results
Effects ofRX-465 on cell morphology ofHT1080 cells
Human fibrosarcoma HT1080 cells. cultured with RX-465 for
48 h at 2 0tM, showed an altered morphology (Figure 2). The
parental HT1080 cells displayed a spindle-shaped, refractile
and disoriented appearance, grew densely and aggregated
upon each other, whereas HT1080 cells treated with RX-465
appeared to be larger than the parental cells, acquired flat
morphology indistinguishable from normal epithelium-like
cells, and grew as a strict monolayer with little evidence of
cellular piling.
Effects ofRX-465 on anchorage-dependent growth ofHT1080
cells
As shown in Figure 3, HT1080 cells treated with RX-465
grew at a much slower rate in a dose-dependent manner,
compared with parental cells. The doubling time for HT1080
cells treated with 10Jm RX-465 was approximately 79 h,
whereas the parental cells showed a doubling time of 20 h.
Moreover, HT1080 cells cultured with RX-465 grew to a
lower saturation density in a dose-dependent manner on the
8th day after cell plating. The parental cells reached a satura-
a
b
Figwe 2 Phase-contrast photomicrographs of HT1080 human
fibrosarcoma cells treated with (b) or without (a) 2gm RX-465
for 48 h. Bar =I00 Lm.
1Wu
B 10
a)
Q
.0
E
C
c;
0
x
0.1
0.1I
0 2 4 6
Time (days)
8
Figure 3 A decrease in a growth rate and a saturation density in
HT1080 human fibrosarcoma cells by treatment with RX-465-
HT1080 cells were plated at 2.5 x I10 cells per well on a 24-well
tissue culture plate on day 0. The next day they were treated with
medium containing 1 pM (0). 3 iM (A) or IOiM (0) RX-465 or
vehicle control (-). The medium was changed on days 3 and 5.
At the appropriate time interval the number of cells was counted.
The data obtained represent the averages of measurements made
on three wells. Similar results were obtained in three separate
experiments.
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I fuv% _rtion density of 1.6 x 10' cells per well in a 24-well plate. In
contrast, revertant cells treated with 10 Jim RX-465 exhibited
a growth density that was 10-fold lower than that of the
parental cells. The effects of RX-465 on both growth rate
and saturation density was not apparently associated with
either acute or delayed cytotoxicty; revertant cells which had
reached confluence with 10FM RX-465 were able to exchlde
trypan blue. On re-inoculation into a culture plate with
culture medium containing RX-465, all of the revertant cells
were able to attach and grow at almost the same rate as
shown in Figure 3 without any cytotoxicity. Removal of this
compound from culture medium resulted in restoration to the
orginal morphology and growth rate during passage 3.
Effects ofRX-465 on anchorage-independent growth of
HTl&OS cells
RX-465 has a potent, dose-dependent inhibitory effect on
anchorage-independent cell growth. Revertant cells induced
by RX-465 over a 2 day period showed hardly any colony
formation in soft apr, i.e. at only 20% and 10% ofcontroL
at 1 JAm and 2gM resectively (Figure 4). The object of
eiminating RX-465 from soft apr was to examie the
biological characteristics of HT1080 cells at the point of
acquiring the observably flat morphology. The revertant cells
in soft apr culture without RX-465 retained the loss of this
transformed property as distingished from those in liquid
culture.
Effects ofRX-465 on twnorigenicity ofHT1080 cells
In order to investigate whether the RX-465 revertants lose
the ability to produce tumours in vivo, we eamine the
effects of RX-465 on the tumorigenicity of HT1080 cells in
athymic mice. After treatment with 2#M RX-465 for 48 h,
HT1080 cells, freed from RX-465 by a wash procedure and
able to exchlde trypan blue, were inoculated s.c. into athymic
mice. On the 17th day after inoculation, the revertant cells
induced with RX-465 grew at a slower rate than those
treated with vehide controL with an 88% reduction in the
average weight of the tumours (Figure 5). With regard to
tumour indence, the cells cultured with vehicle control
induced tumour formation in all mice. In contrast, no growth
ofthose revertant cells cultured with RX-465 was observed in
four out of the eight athymic mice. In addition, these cells
failed to produce tumours in the subsequent 4month obser-
vation period of these four mice. Absence of tumour was
confirmed by detailed autopsy of one of the four mice.
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Flgwe 4 Inhibition of achorage-independent growth of
HT10O8 human fibrosarcoma cells by treatment with RX-465.
HT1080 cells were grown with or without I gm or 2pm RX-465
for 2 days. The cels were harvested and washed to remove
RX-465. The viable cells that could excude trypan blue dye were
plated at I x 103 cells per well into a 24-wel tissue culture plate
in 0.3% apr with DMEM supplemnted with 10"!. FBS. After
12 days the number of colonies forming 0.1 mm in diameter per
wel was counted. The data obtained represent the average
percentage of the colonies ma two weils. Similar results were
obtained in two separate expements.
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Effects ofRX-465 on anchorage-dependent growth and cell
morphology in tumour cell lines andnormal diploid cell lines
We examined the effect ofRX465 on other cell lines in terms
of cell growth and cell morphology to clarify whether the
morphological change is restricted only to human fibrosar-
coma HT1080 cells. Table I shows that RX465 had a potent
growth-inhibitory effect against L-929, B16 melanoma, K-
BALB, P388 leukaenia, and T24 carcnoma as well as
HT1080 fibrosarcoma. However, it had little effect on growth
of PA-1 teratocarcinoma, diploid fibroblast MRC-5, WI-38
and IMR-90. In other words, RX465 had approximately
100-fold specificity to the former lines compared with the
latter ones. We also found that RX465 induced flat cell
morphology in L-929 and B16 melanoma as observed in
HT1080 cells. In contrast, there were some cell lnes such as
K-BALB, P388 and T24 whose growth was inhibited by
RX-465 without morphological changes.
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F4ue 5 Inhibition of tumorigenicity of HT1I8O human
fibrosacoma cells by treatment with RX-465. HT 1080 cells
which had been tmated with or without 2gm RX-465 for 48 h
wer harvested and washed so as to be free from RX-465.
Approximately I x 10' viae cels that could xclude trpn blue
dye were inoculaed sc. into athymic nude mice aged 6 weeks.
After 17 days, the formed tumwurs were taken out and measured
for weight Circes, individual tumour wfight; bars, mcan ± s.e.;
n= 10 (control group), n= 8 (RX-465-treated group).
*Signfiantly smaler than untreated control group (P<0.001).
Similar results wme obtained in three separatc experiments.
Table I Effect of RX-465 on anchorage-ependent growth and cell
morpholog in tumour cell hmes and normal diploid cell lies
Species Cellln Ras IC5,,(gw), Ka cell Mopoogyb
Murine L-929 H', K' 0.6 Yes
B16 Hd, K' 1.6 Yes
K-BALB Kf 0.7 No
P388 N' 0.8 No
Human HT1080 N 2.0 Yes
T24 Hi 0.8 No
PA-i N' > 100 No
Human MRC-5 50 No
WI-38 80 No
IMR-90 > 100 No
aConcentration producig 50% cell growth inhibition when cels
with vehicle control reached a saturation density. bMorpolog was
obsrved after 72 h teatment of 10pm RX-465. Ras activmon
described by 'Abken et al. (1990), Prasad et al. (1990), "Kris et al.
(1985), 'Aaronson & Weaver (1971), qiu et al. (1993), Arends et al.
(1993), atainsky et al. (1988).
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The studies described here have shown that a novel styryl
diphenylamine derivative, RX-465, reduces the malignant
phenotype of human fibrosarcoma HT1080 cells, including
features such as rapid rates of proliferation accompanied by
cellular piling, high saturation density at confluence,
anchorage-independent growth in soft agar and tumori-
genicity in nude mice. The revertant cells treated with RX-
465 displayed a slower growth rate compared with cells
treated with control vehicle, accompanied by morphological
alterations of a flattened appearance which closely resembled
revertants obtained by Paterson et al. (1987) as selected from
HT1080 cells by a suicide technique. It is apparent that the
slower growth rate in HT1080 cells treated with RX-465
could not be attributed to anomalous factors such as either
acute or delayed cytotoxicity because the reproducibility in
their growth rate was observed when the revertant cells were
reioculated after achieving confluence. As a consequence of
the simple reductions in mutant p2l1, as observed by
Paterson et al. (1987), similar morphological changes in
HT1080 cells treated with RX-465 might indcate the pos-
sibility of a role for this compound in counteracting neoplas-
tic transformation. Moreover, treatment ofHT1080 cells with
RX-465 resulted in a lower saturation density and inhibition
ofanchorage-independent growth in soft agar, both ofwhich
characteristics have been associated with reduction oftumour
formation in mice, the most crifical phenotypic measure of
cell transformation. (Aaronson and Todaro, 1968; Freedman
et al., 1974). In terms of the relationship between the
capability ofcell transformation in vitro and in vivo, there are
some exceptions. Not all revertant cells which show a
decrease in saturation density and a complete loss ofcapacity
for anchorage-independent growth, also show a reduction of
tumorigenicity in vivo because of phenotypic instability
(Haynes and Downing, 1988). In this context the reduction
of the tumorigenicity observed with HT1080 cells treated
with RX-465 can be understood to demonstrate that the
revertant cells have a stable phenotype which can contribute
to the reduction of proliferation in vivo. Instability of the
revertant phenotype after elimination of RX-465 was only
observed during passage 3 in monolayer culture. This is
perhaps because certain unkrnown key factors that are
epigenetic components which influence growth regulation are
abolished in continuous culture. Also, the frequency of rever-
sion was 96% (1569 out of 1635 cells slcted at random)
after 7 days' treatment with 10pM RX-465 in HT1080 cells,
which suggests that a small number ofthe cells that can resist
RX-465 treatment were able to proliferate and dominate
culture characterisics after passage 3. Some of the charac-
teristics of maligant tumour cells are cell density-
indepenent proliferation, anchorage-independent growth
and tumorigenicity in nude mice. A styryl diphenylaine
derivative able to diminish these transforming activities could
help to elucidate the molecular basis ofcell transformation in
malignant tumours.
The mechanism by which this styryl diphenylamine
derivative reverts the transformed phenotype ofhuman fibro-
sarcoma HT1080 cells is still unknown. In our initial studies,
we speculated on the basis of the study performed by Pater-
son et al. (1987) that the derivative might reduce cellular
concentration ofmutant p2l'. However, we found that the
alteration to flat cell morphology was observed in three out
of seven cancer cell lines which exhibit ras activation, sug-
gesting that RX-465 may not necessarily revert the phenotype
of every tumour cell that contains activated ras oncogenes.
Therefore, we speculate that the cellular reversion is rarely
attributed to a depletion of ras function, although it is
apparent that this phenomenon is not restricted only to
HT1080 fibrosarcoma cells. Intrestingly, this compound
exerted strong growth inhibitory activity in six out of seven
cancer cell lines and had little cytotoxicity in three human
normal diploid fibroblast lines. Taken together, our results
suggest that RX-465 may have specificity for growth inhibi-
tion of tumour cells, including some morphological effects.
Next we investigated whether this reversion on the trans-
formed phenotype is associated with tyrosine protein kinase
(TPK) activity since RX-465 is similar in chemical structure
to TPK inhibitors such as erbstatin, classified with 'styryl-
based' inhibitors (Smyth et al., 1993). However, on direct
assay of TPK activity we found no evidence for a relation-
ship between signal tansductions induced by TPK and the
reversion by RX-465 (unpublished data). As a consequence,
we speculate that RX-465 may play an important role in the
counteraction of common cellular events, independent of ras
functions among L-929, B16 melanoma and HT1080 fibro-
sarcoma cells.
In conclusion, we have discovered that a styryl diphenyl-
amine derivative, RX-465, reverts the transformed phenotype
of human fibrosarcoma cell line HT1080 at low micromolar
concentrations. RX-465 induces a flat cell morphology and a
reduction in the proliferative rate. Moreover, the revertant
cells exhibit a low saturation density at confluence, lose the
ability to proliferate in soft agar and were for the most part
unable to induce tumour formation in athymic mice. RX-465
appears to exert no cytotoxic effects on untransformed cells.
It is tempting to seculate that RX-465 may be important in
cancer chemotherapy.
HBSS, Hanks' balanced salt solution; PBS, Ca2+- and Mg2+-free
phosphate-buffered saline; s.c., subcutaneous; IC5o, concentration
producing 50% cell growth inhibition; Hepes, 4-(2-hydroxyethyl)-l-
pip_ainetInsulphonic acid.
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